Potent reversible inhibitors of the protein tyrosine phosphatase CD45

Journal of Medicinal Chemistry

Volumn 44, Issue 11, 2001, Pages 1777-1793

  Urbanek, R A ^a   Suchard, S J ^b   Steelman, G B ^a   Knappenberger, K S ^a   Sygowski, L A ^a   Veale, C A ^a   Chapdelaine, M J ^a  

^a ASTRAZENECA   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9,10 PHENANTHRENEDIONE DERIVATIVE; PHENANTHRENE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; T LYMPHOCYTE;

ANTIGENS, CD45; CELL DIVISION; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; NAPHTHOQUINONES; NITROPHENOLS; OLIGOPEPTIDES; ORGANOPHOSPHORUS COMPOUNDS; PHENANTHRENES; PROTEIN-TYROSINE-PHOSPHATASE; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES;

EID: 0035942509     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000447i     Document Type: Article

References (66)

1. The side-effects of cyclosporine-A and tacrolimus
2. Cyclosporine induces cancer progression by a cell-autonomous mechanism
3. Cyclosporine neurotoxicity: A review
4. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin
5. Rapamycins: Antifungal, antitumor, antiproliferative and immunosuppressive macrolides
6. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine
7. Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: Association of capillary leak syndrome with apoptosis of lesional lymphocytes
8. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506
9. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling
10. From form to function: Signaling by protein tyrosine phosphatase
11. Protein-tyrosine phosphatases: Biological function, structural characteristics, and mechanism of catalysis
12. CD45: An emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development
13. Signal transduction by lymphocyte antigen receptors
14. Intimate association of Thy-1 and the T-cell antigen receptor with the CD45 tyrosine phosphatase
15. Activation of CD45-deficient T cell clones by lectin mitogens but not anti-Thy-1
16. Anti-leukocyte common (CD45) antibodies inhibit dendritic cell stimulation of CD4 and CD8 T-lymphocyte proliferation
17. Inhibition of alloreactivity in vitro by monoclonal antibodies directed against restricted isoforms of the leukocyte-common antigen (CD45)
18. Prevention and reversal of renal allograft rejection by antibody against CD45RB
19. Antibody-mediated targeting of CD45 isoforms: A novel immunotherapeutic strategy
20. Preparation of fluoro- and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine
21. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic L-O-malonyltyrosine
22. Potent inhibition of protein-tyrosine phopshatase 1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT)
23. Radio frequency tag encoded combinatorial library method for the discovery of tripeptide-substituted cinnamic acid inhibitors of the protein tyrosine phosphatase PTP1B
24. Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetic and their use in the preparation of tyrosine phosphatase inhibitory peptides
25. Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors
26. L-O-(2-malonyl)-tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 3 domain inhibitory peptides
27. Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides
28. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics
29. Potent non-peptidyl inhibitors of protein tyrosine phosphatase 1B
30. Inhibition of protein tyrosine phosphatases PTP1B and CD45 by sulfotyrosyl peptides
31. Synthesis and characterization of a novel class of protein tyrosine phosphatase inhibitors
32. Protein tyrosine phosphatase substrate specificity: Size and phosphotyrosine positioning in peptide substrates
33. Phosphopeptide substrates and phosphonopeptide inhibitors of protein-tyrosine phosphatases
34. 2Pmp
35. Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B
36. Crystal structure of human protein tyrosine phosphatase 1B
37. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes
38. Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties
39. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design
40. Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B
41. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction
42. Solvent effects in the fluorination of aromatic molecules with 1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)
43. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein tyrosine phosphatases?
44. Protease inhibitors: Current status and future prospects
45. Palladium-catalyzed cross-coupling reactions of organoboron compounds
46. Oxidation of halophenols and highly substituted phenols with lead(IV) acetate
47. Uber organische katalysatoren, XXV. Mitteil. Katalytische wirkungen von ochinonen
48. Evidence for a new type of substitution reaction of phenanthrene-9,10-quinone derivatives
49. Pre-steady-state and steady-state kinetic analysis of the low molecular weight phosphotyrosyl protein phosphatase from bovine heart
50. The addition of alcohol to 1,2-naphthoquinone promoted by metal ions. A facile synthesis of 4-alkoxy-1,2-naphthoquinones
51. Condensation indole/1,2-naphthoquinone. Recherche de conditions optimales dans la preparation d'une nouvelle serie de 4-(3-indolyl)-1,2-naphthoquinones
52. Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: A paradigm for inhibitor design
53. Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate
54. Characterization and kinetic analysis of the intracellular domain of human protein tyrosine phosphatase β(HPTPβ) using synthetic phosphopeptides
55. Substrate specificities of catalytic fragments of protein tyrosine phosphatases (HPTPβ, LAR, and CD45) toward phosphotyrosylpeptide substrates and thiophosphotyrosylated peptides as inhibitors
56. Cross coupling strategies. A regiospecific route to heteroring-annelated orthonaphthoquinones and a short synthesis of β-lapachone
57. Synthetic routes to indenopyridine analogues of morphactins
58. Differential effects of expression of the CD45 tyrosine protein phosphatase on the tyrosine phosphorylation of the lck, fyn, and c-src tyrosine protein kinases
59. Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition
60. Emerging roles for cysteine proteases in human biology
61. Oxidation of phenols, pyrocatechols, and hydroquinones to ortho-quinones using benzeneseleninic anhydride
62. Reaktionen mit nitrosodisulfonat, V. Mittel.: Uber die bildung von naphthochinon
63. Nitroderivate des phenanthrenchinons
64. Polynitro compounds of fluorene
65. The nitration of 9-bromophenanthrene
66. Cell poliferation